Three-year experience of catheter-based micro-axial left ventricular assist device, Impella, in Japanese patients: the first interim analysis of Japan registry for percutaneous ventricular assist device (J-PVAD)

Toda, Köichi; Ako, Junya; Hirayama, Atsushi; Kinugawa, Koichiro; Kobayashi, Yoshio; Ōno, Minoru; Nishimura, Takashi; Sato, Naoki; Shindo, Takahiro; Takayama, Morimasa; Yasukochi, Satoshi; Shiose, Akira; Sawa, Yoshiki

doi:10.1007/s10047-022-01328-1

Cited by 28 publications

(29 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the initial J-PVAD registry data in which Impella was used with VA-ECMO called as "ECPELLA" in 387 patients (47.3%), overall 30-day survival was 81.1% in patients requiring single Impella support and 49.6% in patients requiring Impella combined with VA-ECMO support (ECPELLA). 23 Recent multicenter studies in the US and Europe found early mortality rates of 60% 24,25 in ECPELLA patients, higher than the rate shown by J-PVAD data. What is unique in J-PVAD data is that they represent a national registry database, and include all patients treated at centers with limited as well as those with extensive experience.…”

Section: Support For Cardiogenic Shockmentioning

confidence: 87%

“…Because participation in a national registry is mandatory for patients with Impella, all patient data were collected by the Japanese Registry for Percutaneous Ventricular Assist Devices (J‐PVAD). According to the initial J‐PVAD registry data in which Impella was used with VA‐ECMO called as "ECPELLA" in 387 patients (47.3%), overall 30‐day survival was 81.1% in patients requiring single Impella support and 49.6% in patients requiring Impella combined with VA‐ECMO support (ECPELLA) 23 . Recent multicenter studies in the US and Europe found early mortality rates of 60% 24,25 in ECPELLA patients, higher than the rate shown by J‐PVAD data.…”

Section: Mechanical Circulatory Support For Cardiogenic Shockmentioning

confidence: 99%

See 1 more Smart Citation

Mechanical circulatory support for adults in Japan: A 10‐year perspective

Toda

Bernhardt²,

Mehra

2023

Artificial Organs

View full text Add to dashboard Cite

Globalization in Asia and consequent strengthening of healthcare economic factors in tandem with an increasing heart failure (HF) population have enhanced potential for development and progress in the fields of HF medicine and mechanical circulatory support (MCS). In Japan, there are unique opportunities to investigate the outcome of acute and chronic MCS and a national registry for percutaneous and implantable left ventricular assist device (LVAD) including Impella pumps has been established. A Peripheral extracorporeal membrane oxygenation (ECMO) for acute MCS has been used in more than 7000 patients annually and Impella usage in more than 4000 patients over the past 4 years was noted. Recently, a novel centrifugal pump with hydrodynamically levitated impeller was developed and approved for mid‐term extracorporeal circulatory support. In terms of chronic MCS more than 1200 continuous flow LVADs have been implanted during the past decade, and 2‐year survival rate after primary LVAD implantation is 91%. Because of donor organ shortage, more than 70% of heart transplant recipients required LVAD support for more than 3 years and prevention and treatment of complications during long‐term LVAD support have become important. Five important topics including hemocompatibility‐related complications, LVAD infections, aortic valve insufficiency, right ventricular failure and cardiac recovery during LVAD support are discussed in this review for improving clinical outcomes. Findings from Japan will continue to provide useful information regarding MCS for the Asia‐Pacific region and beyond.

show abstract

Section: Support For Cardiogenic Shockmentioning

confidence: 87%

Section: Mechanical Circulatory Support For Cardiogenic Shockmentioning

confidence: 99%

Mechanical circulatory support for adults in Japan: A 10‐year perspective

Toda

Bernhardt²,

Mehra

2023

Artificial Organs

View full text Add to dashboard Cite

show abstract

“…Finally, the recently published J-PVAD 12 data demonstrated a 30-day survival of 80.9% in CS-AMI patients treated with Impella.…”

mentioning

confidence: 82%

Mechanical circulatory support in cardiogenic shock: it is not just a matter of device

Pappalardo

Montisci

2023

Journal of Cardiovascular Medicine

View full text Add to dashboard Cite

Cardiogenic shock after acute myocardial infarction (CS-AMI) occurs in up to 10% of all acute myocardial infarctions and, despite the advancement of coronary reperfusion therapies and the development of multiple mechanical circulatory support (MCS) devices, is still associated with a 30-day mortality rate of 40%. 1 Absence of adequately powered randomized controlled trials, 2,3 conflicting retrospective studies, 4 and promising results coming from recent protocol-driven prospective studies dominate the landscape of MCS on CS-AMI patients. 5

show abstract

“…10 The first interim analysis of J-PVAD has been recently published elsewhere. 11 In this second interim analysis of J-PVAD, Ikeda et al aimed to analyze efficacy and safety profiles of Impella devices in Japanese patients with AMICS. The study period was from October 2017 to January 2020.…”

Section: New Landscape Of Acute Myocardial Infarction Complicated By ...mentioning

confidence: 99%

New Landscape of Acute Myocardial Infarction Complicated by Cardiogenic Shock With the Advent of a Small But Mighty Heart Pump

Godo

Yasuda

2023

Circ J

View full text Add to dashboard Cite

Three-year experience of catheter-based micro-axial left ventricular assist device, Impella, in Japanese patients: the first interim analysis of Japan registry for percutaneous ventricular assist device (J-PVAD)

Cited by 28 publications

References 17 publications

Mechanical circulatory support for adults in Japan: A 10‐year perspective

Mechanical circulatory support for adults in Japan: A 10‐year perspective

Mechanical circulatory support in cardiogenic shock: it is not just a matter of device

New Landscape of Acute Myocardial Infarction Complicated by Cardiogenic Shock With the Advent of a Small But Mighty Heart Pump

Contact Info

Product

Resources

About